ELAB

Strategic consolidation of two precision manufacturing portfolio companies expected to streamline operations, shared resources, and strengthen the companies' aerospace manufacturing platform NEWPORT BEACH, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”) today announced that it has merged AGA Precision Systems LLC (“AGA”) into A&B Aerospace, Inc. (“A&B Aerospace”), with A&B Aerospace expected to be the surviving operating entity.

Three emerging biotechnology companies, Can-Fite (NYSE: CANF), NeOnc (NASDAQ: NTHI), and PMGC (NASDAQ: ELAB) are pursuing a distinct therapeutic strategy

Yuva Biosciences' proprietary MitoNova™ AI platform identified small-molecule candidates that were biologically validated in primary human skeletal muscle cells, with multiple candidates increasing ANT1, a mitochondrial protein central to skeletal muscle energy metabolism. Four AI-selected compounds demonstrated ANT1 induction, supporting their further confirmatory testing and development.

Filed applications include claims directed to the use of EL-22 and EL-32 for preserving lean muscle mass during GLP-1 and obesity-related weight loss Filed applications include combination and co-administration approaches, including taking EL-22 or EL-32 together with apelin or ursolic acid, compounds associated with muscle support NEWPORT BEACH, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) ("PMGC" or the "Company") today announced that its wholly-owned subsidiary, NorthStrive Biosciences, Inc. ("NorthStrive"), has filed two new U.S. patent applications expanding the Company's EL-22 and EL-32 intellectual property portfolio into potential human pharmaceutical applications for the preservation of lean muscle mass during GLP-1 and obesity-related weight loss.

A&B Aerospace, SVM Machining, and AGA Precision Systems Position PMGC's Precision Manufacturing Platform to Serve Growing Demand Across Satellites, Launch Systems, and Space Infrastructure, such as Space Data Centers NEWPORT BEACH, Calif., June 10, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (NASDAQ: ELAB) (the “Company,” “PMGC,” “we,” or “our”), a diversified holding company, highlights that its current precision manufacturing operating subsidiaries currently serve and have the opportunity to further capitalize of the current Space exploration industry growth.

PMGC Holdings Signs Non-Binding Letter of Intent to Acquire Majority Stake in U.S.-Based Precision Machining Manufacturing Company Serving Aerospace, Space

VANCOUVER, British Columbia, May 18, 2026 (GLOBE NEWSWIRE) -- GB Capital Ltd. ("GB Capital"), a strategic finance, advisory and management firm, today announced that it served as co-advisor to PMGC Holdings Inc. (NASDAQ: ELAB) ("PMGC") on PMGC's acquisition of A&B Aerospace, Inc. ("A&B Aerospace" or "A&B"), an AS9100D and ISO 9001:2015 certified precision machining and aerospace manufacturing company headquartered in Azusa, California.

PMGC Holdings Inc. [NASDAQ: ELAB] Reports Q1 2026 Results and Files Form 10-Q; Total Assets Reach Over $26.0 Million, Up 102% from Year-End 2025 and 193% Y

Precision machining and aerospace, defense manufacturing company contracted by long standing Tier 1 customers that include Boeing, Honeywell International Inc., and Moog Inc.* AS9100D and ISO 9001:2015 certified NEWPORT BEACH, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC” or the “Company”), a diversified holding company currently executing a targeted roll-up strategy in U.S.-based precision manufacturing companies, has acquired A&B Aerospace, Inc. (“A&B Aerospace” or “A&B”), Founded in 1948, A&B Aerospace is a precision machining and aerospace manufacturing company specializing in high-tolerance parts and assemblies for the aerospace industry.

Filing seeks to extend EL-22 myostatin-engineered probiotic platform into pharmaceutical applications for muscle preservation in patients on GLP-1 receptor agonists and across multiple muscle-wasting indications NEWPORT BEACH, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (“NorthStrive” or the “Company”), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB) (“PMGC”), today announced the filing of a new U.S. patent application covering pharmaceutical formulations and dosing regimens of EL-22, the Company's proprietary myostatin-engineered probiotic, for the treatment of muscle-wasting conditions, including muscle loss associated with GLP-1 receptor agonist therapy, sarcopenia, muscle disuse atrophy, and certain neurological disorders.